Skip to main content

Rapaflo FDA Approval History

FDA Approved: Yes (First approved October 8, 2008)
Brand name: Rapaflo
Generic name: silodosin
Dosage form: Capsules
Company: AbbVie Inc.
Treatment for: Benign Prostatic Hyperplasia

Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.

Development timeline for Rapaflo

DateArticle
Oct  9, 2008Approval Watson Receives US FDA Approval for Rapaflo (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
Feb 12, 2008Watson Announces Silodosin NDA Accepted for Filing by FDA for theTreatment of Benign Prostatic Hyperplasia

See also

Rapaflo (silodosin) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer